Whitepaper: Bridging the cell and gene therapy gap

The current understanding among sponsors of the workflow from cell collection, to manufacturing, and to the clinical site for patient administration.

With the rise of the development of cell and gene therapies (CGT) and their associated clinical trials, it is becoming increasingly important to bridge the knowledge and service gaps from manufacturing these advanced therapies to the end-to-end supply chain management. A survey was conducted by Catalent and Fierce Biotech to better understand current perceptions of these gaps by individuals in the CGT industry, including specialized supply chain needs associated with these types of studies.